PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-15.16%
Both yoy net incomes decline, with TRAW at -3.01%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
8.11%
D&A growth of 8.11% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
14.88%
Deferred tax of 14.88% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
33.33%
SBC growth well above TRAW's 4.44%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-359.86%
Negative yoy working capital usage while TRAW is 63.18%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-185.03%
Negative yoy usage while TRAW is 1312.88%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-14.88%
Negative yoy while TRAW is 358.93%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-25.31%
Negative yoy CFO while TRAW is 5.12%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-2962.50%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2962.50%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
56.30%
Debt repayment growth of 56.30% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
23135.79%
Issuance growth of 23135.79% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
100.00%
Buyback growth of 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.